Comparative Pharmacology
Head-to-head clinical analysis: MACITENTAN versus OPSYNVI.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MACITENTAN versus OPSYNVI.
MACITENTAN vs OPSYNVI
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Endothelin receptor antagonist (ERA) that blocks the binding of endothelin-1 (ET-1) to ETA and ETB receptors, thereby inhibiting vasoconstriction and smooth muscle proliferation.
OPSYNVI is a dual endothelin receptor antagonist (ERA) and phosphodiesterase-5 (PDE5) inhibitor. Macitentan blocks endothelin-1 (ET-1) receptors (ETA and ETB), reducing vasoconstriction and proliferation. Tadalafil inhibits PDE5, increasing cGMP levels and causing vasodilation.
10 mg orally once daily.
10 mg orally once daily, in combination with tadalafil 20 mg orally once daily.
None Documented
None Documented
Terminal elimination half-life is 11–22 hours in healthy subjects; in pulmonary arterial hypertension patients, mean half-life is approximately 13 hours.
Clinical Note
moderateMacitentan + Methylphenidate
"Macitentan may decrease the antihypertensive activities of Methylphenidate."
Clinical Note
moderateMacitentan + Sulfisoxazole
"The metabolism of Sulfisoxazole can be decreased when combined with Macitentan."
Clinical Note
moderateMacitentan + Erythromycin
"The metabolism of Erythromycin can be decreased when combined with Macitentan."
Clinical Note
moderateMacitentan + Cyclosporine
Terminal elimination half-life approximately 15 hours (range 10–20 hours) in patients with pulmonary arterial hypertension; supports twice-daily dosing.
Biliary/fecal (major, 93% as metabolites) and renal (3% unchanged, <5% of dose in urine).
Primarily fecal (approximately 66% of absorbed dose) and renal (approximately 22% as unchanged drug and metabolites). Biliary excretion is negligible.
Category D/X
Category C
Endothelin Receptor Antagonist
Endothelin Receptor Antagonist/Phosphodiesterase-5 Inhibitor Combination (PAH)
"The metabolism of Cyclosporine can be decreased when combined with Macitentan."